Pharmacy Department, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria, 3002, Australia.
J Hematol Oncol. 2013 Jan 4;6:1. doi: 10.1186/1756-8722-6-1.
Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.
抗体依赖的细胞细胞毒性 (ADCC) 是治疗性单克隆抗体 (mAb)（如西妥昔单抗、利妥昔单抗和曲妥珠单抗）的主要作用机制。人类白细胞上的 Fc 受体 (FcgR) 是 ADCC 途径的一个组成部分。据报道，对治疗性 mAb 的不同反应与这两个基因中的两个特定多态性相关：FCGR2A (H131R) 和 FCGR3A (V158F)。这些多态性与受体对 mAb 的不同亲和力相关。本文批判性地审查了目前对相应单核苷酸多态性 (SNP) 进行基因分型以预测癌症患者对 mAb 反应的证据。
